STOCK TITAN

Insulet Corporation - PODD STOCK NEWS

Welcome to our dedicated page for Insulet Corporation news (Ticker: PODD), a resource for investors and traders seeking the latest updates and insights on Insulet Corporation stock.

Insulet Corporation (symbol: PODD) is a pioneering medical device company headquartered in Billerica, Massachusetts. Founded in 2000, the company is dedicated to improving the lives of people with diabetes through its innovative Omnipod Insulin Management System. The Omnipod system revolutionizes insulin pump therapy by making it more accessible and user-friendly compared to traditional methods.

The Omnipod system offers several advantages over multiple daily insulin injections (MDI), including better glycemic control, fewer hypoglycemic events, reduced glycemic variability, and improved quality of life. Despite these benefits, the complexity, cost, and inconvenience of conventional insulin pump technology have deterred many from adopting pump therapy. Insulet's Omnipod addresses these challenges by providing a discreet, tubeless, and easy-to-use system that automates the process and ensures virtually pain-free insertion. The system consists of only two parts that communicate wirelessly, streamlining the user experience.

Since its approval by the U.S. Food and Drug Administration in 2005, the Omnipod has been adopted by approximately 425,000 insulin-dependent diabetics worldwide. This level of adoption underscores the effectiveness and user satisfaction associated with Insulet's flagship product. The Omnipod is notable for its disposable, smartphone-controlled insulin infusion device, which enhances the convenience and flexibility of insulin therapy.

Insulet continues to innovate and expand its product offerings. The company is currently engaged in multiple projects aimed at further improving diabetes management and enhancing the quality of life for its users. Financially, Insulet maintains a strong position, driven by robust sales growth and strategic partnerships that support its mission.

Overall, Insulet Corporation stands out in the medical device industry for its commitment to innovation and its impact on the diabetes community. Investors and stakeholders can expect continued advancements and a strong financial performance as the company pursues its mission to simplify and improve insulin management.

Rhea-AI Summary
Insulet Corporation (PODD) announces new appointments to its Board of Directors and the retirement of two board members. Flavia Pease and Timothy Stonesifer will join the Board, while Shacey Petrovic and Corinne Nevinny will retire at the Company's 2024 Annual Meeting. The new appointees bring extensive industry expertise and distinguished careers to support and enhance the company's commitment to excellence and innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
management
-
Rhea-AI Summary
Insulet Corporation (PODD) to Release Q4 and Full Year 2023 Financial Results on February 22, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.21%
Tags
-
Rhea-AI Summary
Insulet Corporation (PODD) to present at Nasdaq 29th Investor Conference in London and J.P. Morgan Annual Healthcare Conference in San Francisco. Live audio webcasts and replays available on investors.insulet.com/events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
conferences
Rhea-AI Summary
Insulet Corporation (NASDAQ: PODD) announced its financial results for the third quarter of 2023. The company reported revenue of $432.7 million, up 27.0% compared to the prior year. Gross margin increased to 67.8%, and operating income increased to $54.8 million. Net income was $51.9 million, compared to a net loss of $5.2 million in the prior year. The company raised its full-year revenue guidance to a range of 26% to 27%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.76%
Tags
-
Rhea-AI Summary
Insulet Corporation announced a series of initiatives in recognition of National Diabetes Awareness Month and World Diabetes Day. The company will ring the closing bell at Nasdaq Stock Market on November 14 and will host educational events. Insulet is committed to raising awareness and providing support for people with diabetes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.88%
Tags
none
-
Rhea-AI Summary
Sensata Technologies announced that Brian K. Roberts has been named as the new CFO, succeeding Paul Vasington who will retire. Brian will assume leadership of all global financial activities. Brian brings decades of finance and leadership experience, including as CFO at Insulet Corporation and Digitas, Inc. Sensata will conduct a conference call to discuss its Q3 2023 financial results and outlook for Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
none
Rhea-AI Summary
Insulet Corporation has received FDA clearance for the Omnipod 5 App for iPhone, making it the first company to offer a tubeless automated insulin delivery system with full control from a compatible Android and iOS smartphone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.57%
Tags
-
News
Rhea-AI Summary
Insulet Corporation reaffirms guidance for Q3 and FY 2023, announces CFO resignation and interim replacement
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.02%
Tags
none
-
Rhea-AI Summary
Insulet Corporation announces schedule of events and presentations at EASD 2023, highlighting extended real-world evidence of improved outcomes using Omnipod 5 Automated Insulin Delivery System.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.48%
Tags
conferences
Rhea-AI Summary
Insulet Corporation plans to release its financial results for Q3 2023 on November 2, 2023. A conference call will be hosted at 4:30 p.m. (Eastern Time).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags

FAQ

What is the current stock price of Insulet Corporation (PODD)?

The current stock price of Insulet Corporation (PODD) is $266.57 as of December 20, 2024.

What is the market cap of Insulet Corporation (PODD)?

The market cap of Insulet Corporation (PODD) is approximately 18.0B.

What is the main product of Insulet Corporation?

Insulet's main product is the Omnipod Insulin Management System, an innovative insulin pump therapy solution.

Where is Insulet Corporation headquartered?

Insulet Corporation is headquartered in Billerica, Massachusetts.

When was Insulet Corporation founded?

Insulet Corporation was founded in the year 2000.

How does the Omnipod system benefit users compared to multiple daily insulin injections (MDI)?

The Omnipod system offers better glycemic control, fewer hypoglycemic events, reduced glycemic variability, and improved quality of life compared to MDI.

How many people worldwide use the Omnipod system?

Approximately 425,000 insulin-dependent diabetics worldwide use the Omnipod system.

What makes the Omnipod system different from conventional insulin pumps?

The Omnipod system is tubeless, discreet, and easy to use with automated, virtually pain-free insertion and wireless communication between its parts.

When was the Omnipod system approved by the FDA?

The Omnipod system was approved by the U.S. Food and Drug Administration in 2005.

How does the Omnipod system enhance user convenience?

The Omnipod system enhances convenience with its smartphone-controlled insulin infusion device and simplified user experience.

What is Insulet Corporation's mission?

Insulet's mission is to improve the lives of people with diabetes by making continuous subcutaneous insulin infusion therapy easier to use.

What are Insulet Corporation's recent achievements?

Insulet continues to innovate and expand, with strong sales growth and strategic partnerships supporting its mission to enhance diabetes management.

Insulet Corporation

Nasdaq:PODD

PODD Rankings

PODD Stock Data

18.00B
69.75M
0.34%
103.31%
4.29%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
ACTON